Health Care • Biotechnology: Pharmaceutical Preparations
$4.95 ▼ -0.07
(-1.39%)
MKT CAP: $1.02B • VOL: 1.74M
52W L $4 52W H $7
ROARABLE / RQD
D- • 43/100
PIOTROSKI
3 / 9
SVRA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$123.5M | -$103.2M | -$60.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$118.8M | -$95.9M | -$54.7M |
| EBITDA (Normalized) | -$123.5M | -$103.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$101.0M | -$89.1M | -$51.1M |
| Capital Expenditures (CapEx) | $22.0K | $25.0K | — |
| Free Cash Flow (FCF) | -$101.1M | -$89.1M | -$51.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -44.6% | — |
| Cash & Short-Term Equivalents | $33.2M | $15.1M | — |
| Total Debt (Short + Long Term) | $29.9M | $26.6M | — |
| Total Stockholders' Equity | $203.1M | $171.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SVRA.